中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 9
Sep.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(9): 2154-2161

Impact of sarcopenia on short-term prognosis of acute-on-chronic liver failure and the predictive gain of combining traditional scoring systems

DOI: 10.12449/JCH260920
  • 1.

    First Clinical Medical College of Inner Mongolia Medical University，Hohhot 010050，China

  • 2.

    Department of Gastroenterology，The Affiliated Hospital of Inner Mongolia Medical University，Hohhot 010050，China

  • 3.

    Department of Critical Care Medicine，No. 2 Hospital of Hohhot，Hohhot 010050，China

  • 4.

    Department of Gastroenterology，Hohhot First Hospital，Hohhot 010050，China

  • 5.

    Department of Gastroenterology，Inner Mongolia People’s Hospital，Hohhot 010050，China

Research funding:

Natural Science Foundation of Inner Mongolia Autonomous Region (2025ZD009);

Natural Science Foundation of Inner Mongolia Autonomous Region (2023QN08061);

Youth Foundation of Inner Mongolia Medical University (YKD2023QN014);

High-level Talent Training Program of the “Grassland Elite” Project (2022) 

More Information
  • Corresponding author: Li Yanmei， 1218520884@qq.com （ORCID： 0009-0005-4677-4057）
  • Received Date: 2025-09-02
  • Accepted Date: 2026-04-30
  • Published Date: 2026-09-25
    Abstract
  •   Objective  To investigate the association between sarcopenia and short-term prognosis in patients with acute-on-chronic liver failure （ACLF）， to assess the value of Model for End-Stage Liver Disease （MELD）， MELD combined with serum sodium concentration （MELD-Na）， MELD 3.0， and Chinese Group on the Study of Severe Hepatitis B （COSSH）-ACLF Ⅱ score in predicting the 90-day prognosis of ACLF patients， and to analyze the predictive gain of sarcopenia over traditional prognostic scoring models.  Methods  A retrospective study was conducted among 219 patients with ACLF who were hospitalized in The Affiliated Hospital of Inner Mongolia Medical University， No. 2 Hospital of Hohhot， Hohhot First Hospital， and Inner Mongolia People’s Hospital from July 2018 to July 2024. L3 skeletal muscle index （L3-SMI） was measured and calculated based on abdominal computed tomography images， and sarcopenia was diagnosed based on L3-SMI. According to 90-day prognosis， the patients with ACLF were divided into survival group with 124 patients and death group with 95 patients. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups； the independent samples t-test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The multivariate Cox regression analysis （stepwise backward approach） was used to identify independent risk factors for 90-day mortality in ACLF patients. The Kaplan-Meier method was used for survival analysis， and the Log-rank test was used for comparison between groups. The receiver operating characteristic curve was plotted to evaluate the predictive performance of each model， and the DeLong test， bootstrap internal validation， net reclassification improvement （NRI）， and integrated discrimination improvement （IDI） were used to assess the predictive gain of sarcopenia.  Results  The multivariate Cox regression analysis showed that presence of sarcopenia （hazard ratio ［HR］=3.385， 95% confidence interval ［CI］： 1.722 — 6.657， P<0.05）， older age （HR=1.036， 95%CI： 1.017 — 1.056， P<0.05）， elevated alkaline phosphatase （HR=1.006， 95%CI： 1.004 — 1.009， P<0.05）， elevated total bilirubin （HR=1.003， 95%CI： 1.001 — 1.005， P<0.05）， elevated potassium （HR=1.581， 95%CI： 1.160 — 2.155， P<0.05）， elevated serum creatinine （HR=1.015， 95%CI： 1.007 — 1.024， P<0.05）， and prolonged prothrombin time （HR=1.035， 95%CI： 1.015 — 1.055， P<0.05） were independent risk factors for 90-day mortality in ACLF patients， while elevated albumin （HR=0.885， 95%CI： 0.837 — 0.935， P<0.05） was an independent protective factor against 90-day mortality. MELD， MELD-Na， MELD 3.0， and COSSH-ACLF Ⅱ scores had an area under the ROC curve （AUC） of 0.569， 0.570， 0.632， and 0.659， respectively， for predicting the 90-day prognosis of ACLF patients， suggesting that these scores had unsatisfactory performance； after they were respectively combined with sarcopenia， the AUC was increased to 0.702， 0.687， 0.723， and 0.728， respectively. The DeLong test， NRI， and IDI analyses showed the combined models had significantly better predictive performance （all P<0.05）.  Conclusion  Sarcopenia is an independent risk factor for 90-day mortality in patients with ACLF. Traditional scoring models have limited predictive performance for 90-day prognosis in ACLF patients， and the combination with sarcopenia significantly improves predictive value， suggesting that sarcopenia can be used as an important supplementary indicator for prognostic evaluation of ACLF in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    Shang Dabao, Xiang Xiaogang. Advances in the pathogenesis and treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37( 4): 765- 769. DOI: 10.3969/j.issn.1001-5256.2021.04.005.

    尚大宝, 项晓刚. 慢加急性肝衰竭的发病机制和治疗进展[J]. 临床肝胆病杂志, 2021, 37( 4): 765- 769. DOI: 10.3969/j.issn.1001-5256.2021.04.005.
    [2]
    Br V K, Sarin S K. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29( 3): 670- 689. DOI: 10.3350/cmh.2022.0103.
    [3]
    Coletta G, Phillips S M. An elusive consensus definition of sarcopenia impedes research and clinical treatment: A narrative review[J]. Ageing Res Rev, 2023, 86: 101883. DOI: 10.1016/j.arr.2023.101883.
    [4]
    Bunchorntavakul C, Reddy K R. Review article: Malnutrition/sarcopenia and frailty in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 51( 1): 64- 77. DOI: 10.1111/apt.15571.
    [5]
    Beumer B R, van Vugt J L A, Sapisochin G, et al. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria[J]. J Cachexia Sarcopenia Muscle, 2022, 13( 5): 2373- 2382. DOI: 10.1002/jcsm.13053.
    [6]
    Barnhill M S, Carey E J. Compartmentalizing risk with sarcopenic obesity[J]. Liver Transplant, 2023, 29( 5): 463- 464. DOI: 10.1097/lvt.0000000000000061.
    [7]
    Lu Xuemei, Yang Yuhang, Wang Kaiti, et al. Research progress on sarcopenia in the field of liver transplantation[J]. Chin J Dig Surg, 2025, 24( 11): 1501- 1506. DOI: 10.3760/cma.j.cn115610-20250818-00539.

    鲁雪梅, 杨宇航, 王恺悌, 等. 肌少症在肝移植领域的研究进展[J]. 中华消化外科杂志, 2025, 24( 11): 1501- 1506. DOI: 10.3760/cma.j.cn115610-20250818-00539.
    [8]
    Sarin S K, Choudhury A, Sharma M K, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
    [9]
    Chen L K, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21( 3): 300- 307. DOI: 10.1016/j.jamda.2019.12.012.
    [10]
    Kong M, Geng N, Zhou Y, et al. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study[J]. Clin Nutr, 2022, 41( 2): 396- 404. DOI: 10.1016/j.clnu.2021.12.003.
    [11]
    Sayer A A, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: Consensus is growing[J]. Age Ageing, 2022, 51( 10): afac220. DOI: 10.1093/ageing/afac220.
    [12]
    Tantai X X, Liu Y, Yeo Y H, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis[J]. J Hepatol, 2022, 76( 3): 588- 599. DOI: 10.1016/j.jhep.2021.11.006.
    [13]
    Ma L Y, Liu S Q, Xing H, et al. Research progress on short-term prognosis of acute-on-chronic liver failure[J]. Expert Rev Gastroenterol Hepatol, 2023, 17( 1): 45- 57. DOI: 10.1080/17474124.2023.2165063.
    [14]
    Li T Z, Xu M M, Kong M, et al. Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure[J]. Sci Rep, 2021, 11( 1): 12593. DOI: 10.1038/s41598-021-92087-1.
    [15]
    Zeng F, Jiang W, Chang X J, et al. Sarcopenia is associated with short- and long-term mortality in patients with acute-on-chronic liver failure[J]. J Cachexia Sarcopenia Muscle, 2024, 15( 4): 1473- 1482. DOI: 10.1002/jcsm.13501.
    [16]
    Geng N, Kong M, Zhang J T, et al. Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure[J]. Sci Rep, 2024, 14( 1): 13609. DOI: 10.1038/s41598-024-64420-x.
    [17]
    Allen S L, Quinlan J I, Dhaliwal A, et al. Sarcopenia in chronic liver disease: Mechanisms and countermeasures[J]. Am J Physiol Gastrointest Liver Physiol, 2021, 320( 3): G241- G257. DOI: 10.1152/ajpgi.00373.2020.
    [18]
    Cox M C, Booth M, Ghita G, et al. The impact of sarcopenia and acute muscle mass loss on long-term outcomes in critically ill patients with intra-abdominal sepsis[J]. J Cachexia Sarcopenia Muscle, 2021, 12( 5): 1203- 1213. DOI: 10.1002/jcsm.12752.
    [19]
    Mangana del Rio T, Sacleux S C, Vionnet J, et al. Body composition and short-term mortality in patients critically ill with acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5( 8): 100758. DOI: 10.1016/j.jhepr.2023.100758.
    [20]
    Trebicka J, Hernaez R, Shawcross D L, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure(ACLF) and the role of biomarkers[J]. Gut, 2024, 73( 6): 1015- 1024. DOI: 10.1136/gutjnl-2023-330584.
    [21]
    Huang J J, Cai M, He X. Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis[J]. J Clin Lab Anal, 2021, 35( 6): e23775. DOI: 10.1002/jcla.23775.
    [22]
    Wei Guizhi, Fan Feifei, Wang Yutong. Analysis of the causes and prognostic factors of acute liver failure and acute-on-chronic liver failure[J]. Clin Misdiagnosis Mistherapy, 2026, 39( 5): 23- 29. DOI: 10.3969/j.issn.1002-3429.2026.05.005.

    魏桂枝, 樊菲菲, 王玉同. 急性肝功能衰竭及慢加急性肝功能衰竭的病因及预后影响因素分析[J]. 临床误诊误治, 2026, 39( 5): 23- 29. DOI: 10.3969/j.issn.1002-3429.2026.05.005.
    [23]
    Shi S, Yang Y F, Liu Y L, et al. Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system[J]. Front Med, 2024, 11: 1368899. DOI: 10.3389/fmed.2024.1368899.
    [24]
    Chen Jiaoyan, Chen Bin, Cao Dongrong, et al. Risk factors for liver failure-related death in chronic hepatitis B patients[J]. Chin Hepatol, 2021, 26( 9): 994- 997. DOI: 10.14000/j.cnki.issn.1008-1704.2021.09.014.

    陈姣艳, 陈斌, 曹冬容, 等. 慢性乙型肝炎并发肝衰竭死亡危险因素的研究[J]. 肝脏, 2021, 26( 9): 994- 997. DOI: 10.14000/j.cnki.issn.1008-1704.2021.09.014.
    [25]
    Balabanova L, Bondarev G, Seitkalieva A, et al. Insights into alkaline phosphatase anti-inflammatory mechanisms[J]. Biomedicines, 2024, 12( 11): 2502. DOI: 10.3390/biomedicines12112502.
    [26]
    Engelmann C, Adebayo D, Oria M, et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure[J]. Sci Rep, 2020, 10( 1): 389. DOI: 10.1038/s41598-019-57284-z.
    [27]
    Le Couteur D G, Ngu M C, Hunt N J, et al. Liver, ageing and disease[J]. Nat Rev Gastroenterol Hepatol, 2025, 22( 10): 680- 695. DOI: 10.1038/s41575-025-01099-z.
    [28]
    Jiang W Y, Hu Y C, Sun Y, et al. Prevalence and short-term outcome of acute kidney injury in patients with acute-on-chronic liver failure: A meta-analysis[J]. J Viral Hepat, 2020, 27( 8): 810- 817. DOI: 10.1111/jvh.13287.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (78) PDF downloads(14) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return